Rongliflozin L-Pyroglutamic Acid
- Generic Name
- Rongliflozin L-Pyroglutamic Acid
Effects of Rifampicin and Probenecid On The Pharmacokinetic Profile Of Rongliflozin In Healthy Subjects
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Sunshine Lake Pharma Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05497674
- Locations
- 🇨🇳
The First Hospital of Jilin University, Jilin, Changchun, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath